Investor Overview Press Releases January 20, 2021 Aclaris Announces Pricing of Public Offering of Common Stock January 19, 2021 Aclaris Announces Proposed Public Offering of Common Stock January 19, 2021 Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis View all » Events Jan 19, 20218:00 AM EST Aclaris Therapeutics Presents Positive Preliminary Topline Data for ATI-450-RA-201 Dec 2, 20207:30 AM EST Aclaris Therapeutics, Inc. at Evercore ISI 3rd Annual HealthCONx Conference Sep 17, 202010:40 AM EDT Aclaris Therapeutics, Inc. at Cantor Virtual Global Healthcare Conference View all » Feature Presentation ATI-450-RA-201 Phase 2a Preliminary Topline Data Presentation
January 19, 2021 Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Jan 19, 20218:00 AM EST Aclaris Therapeutics Presents Positive Preliminary Topline Data for ATI-450-RA-201